[Corrigendum] Aurora kinase inhibitors:�Potential molecular-targeted drugs for gynecologic malignant tumors (Review)

Subsequently to the publication of the above review article, the authors have realized that they made an error in terms of the description of the Aurora kinase inhibitor, ZM44739. Concerning the sentence in the section ‘3. Clinical applications of Aurora kinase inhibitors’, on p. 337, right-hand column, lines 7-8, the authors wrote ‘ZM447439 was reported as the first Aurora kinase inhibitor in 2003 and is currently in phase I clinical...